NCT04926831View on ClinicalTrials.gov

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

March 13, 2024

Study Completion Date

March 13, 2024

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

capmatinib

150 mg and 200 mg tablets for oral administration

Trial Locations (6)

22031

Fairfax Northern Virginia Hem Onc ., Fairfax

Fairfax Northern Virginia Hem Onc, Fairfax

92037

UCLA Oncology Hematology ., La Jolla

UCLA Oncology Hematology, La Jolla

95817

University of California Davis Cancer Center ., Sacramento

University of California Davis Cancer Center, Sacramento

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY